Chlorogenic acid / LDH Cancer Research Results

Chlorogenic acid — Chlorogenic acid (CGA) is a dietary hydroxycinnamate polyphenol, classically the caffeoyl ester of quinic acid, with 5-O-caffeoylquinic acid as the major canonical form usually meant by “chlorogenic acid.” It is best classified as a small-molecule natural product/polyphenolic phytochemical rather than an approved anticancer drug. Standard abbreviations include CGA and, in chemistry-focused literature, 5-CQA or 5-O-caffeoylquinic acid. Major natural sources include coffee beans, certain fruits, vegetables, and medicinal plants. In oncology, CGA is best viewed as a context-dependent redox, inflammatory, metabolic, and immune-modulatory scaffold with strong preclinical activity but important translation limits because oral systemic exposure is modest and many cell-culture studies use concentrations above likely plasma-achievable levels.

Primary mechanisms (ranked):

1. Redox buffering with suppression of excess ROS and oxidative injury.
2. Keap1/NRF2-axis activation with induction of cytoprotective antioxidant-response programs.
3. Inflammatory signaling suppression, especially NF-κB-linked cytokine and survival programs.
4. Antiproliferative and pro-apoptotic signaling in selected tumor models, often involving Akt, MAPK, mitochondrial stress, and caspase shifts.
5. Metabolic reprogramming effects in some models, including reduced glycolytic signaling and HIF-1α/VEGF-linked adaptation.
6. Immune-modulatory effects, including reported PD-L1 suppression and improved antitumor T-cell activity in some systems.
7. Therapy-interaction effects that can diverge by context, with chemosensitizing reports in some models but radio/chemoprotection risk where antioxidant/NRF2 effects dominate.

Bioavailability / PK relevance: Oral CGA is moderately absorbed and extensively metabolized, not absent from circulation. However, systemic exposure is dominated by conjugated and gut-derived metabolites, while exposure to intact parent CGA is relatively limited and variable. For pharmacology, this means dietary CGA can be biologically relevant, but many in-vitro studies still use concentrations above typical circulating parent-compound levels after ordinary oral intake.

In-vitro vs systemic exposure relevance: This is a major translation constraint. Many oncology papers use roughly 10–200 µM or higher, while realistic oral systemic parent-CGA exposure is usually much lower; therefore many direct cytotoxic, anti-stemness, or signaling claims are likely more relevant to gut/liver first-pass settings, local delivery concepts, metabolite biology, or formulated/injectable products than to ordinary dietary exposure.

Clinical evidence status: Extensive preclinical evidence; limited small-human oncology evidence. Early-phase clinical development exists for injectable CGA in recurrent high-grade glioma/advanced lung cancer programs, but robust randomized evidence for standard anticancer use is not established. Current evidence supports CGA mainly as a preclinical or adjunctive candidate, not a validated standalone cancer therapy.

Plant Source 	       CGA(mg/kg in dw)
Instant coffee  	2650–11,600
Mate tea 	        4800–24,900
Sunflower seeds 	630–970
Sweet potato leaves 	9600
English potato 1 	3.3–9
Okra 1 	                3.9–21.6
Eggplant 	        4980–8050
Carrot 	                300–18,800
Tomato 	                200–400

Chlorogenic Acid Mechanistic Table

Alzheimer’s disease context

Chlorogenic acid — In the Alzheimer’s disease context, chlorogenic acid (CGA) is best classified as a multifunctional dietary polyphenol/neuroprotective small molecule with preclinical cholinergic, antioxidant, anti-inflammatory, and anti-amyloid activity rather than an established AD drug. Its AD relevance is supported by in vitro and animal-model evidence showing reduced acetylcholinesterase activity, lower oxidative stress, lower neuroinflammation, and improved cognitive performance in several paradigms. Standard abbreviations include CGA and 5-CQA. The strongest current interpretation is that CGA is a plausible adjunctive neuroprotective candidate with limited human cognitive-support data, but not a clinically validated treatment for Alzheimer’s disease.

Primary mechanisms (ranked):

1. Reduction of oxidative stress and lipid peroxidation.
2. Suppression of microglial activation and pro-inflammatory signaling.
3. Down-modulation of acetylcholinesterase activity with support of cholinergic tone.
4. Reduction of amyloid-related toxicity and associated neuronal injury.
5. Support of mitochondrial and autophagy-linked neuronal homeostasis in selected models.
6. Functional cognitive improvement in preclinical models, with limited human support for attention/executive domains rather than confirmed AD treatment.

Bioavailability / PK relevance: Oral chlorogenic acids are meaningfully absorbed but extensively metabolized; circulating exposure includes parent compound plus conjugated and gut-derived phenolic metabolites. Brain penetration has been demonstrated in animal PK work, but CNS exposure is still constrained relative to many in vitro concentrations.

In-vitro vs systemic exposure relevance: Many neuroprotection studies use pharmacologic concentrations or dosing paradigms not directly comparable to ordinary dietary intake. AD relevance is therefore biologically plausible but still translationally constrained by metabolism, CNS exposure, and model dependence.

Clinical evidence status: Strong preclinical support; limited human cognitive-support evidence; no convincing clinical evidence that CGA is an established Alzheimer’s disease therapy.

Chlorogenic Acid in Alzheimer’s Disease